" we will want more patients and a longer follow - up to really make a call that the use of crispr is safe . but the data are certainly encouraging , " dr . michel sadelain , an immunologist at the memorial sloan kettering cancer center in new york , told npr . " so far , so good - but [ it is ] still early . "